VPS16: A Potential Drug Target and Biomarker (G64601)

Target Name: VPS16

NCBI ID: G64601

VPS16

VPS16: A Potential Drug Target and Biomarker

VPS16, a gene encoding a voltage-dependent potassium channel subunit, has been identified as a potential drug target and biomarker for various neurological and cardiovascular diseases. The VPS16 gene is located on chromosome 16 and encodes a protein that plays a critical role in the regulation of neuronal excitability and ion channels. The dysfunction of VPS16 has been implicated in a number of neurological and cardiovascular disorders, including epilepsy, bipolar disorder, and hypertension.

Recent studies have suggested that VPS16 may be a drug target by modulating the activity of its associated ion channels. These channels are involved in the regulation of neurotransmitter release, and their dysfunction has been implicated in a number of neurological and psychiatric disorders. The VPS16 gene has also been shown to be involved in the regulation of ion channels in heart muscle, which may be relevant to the development of cardiovascular disease.

In addition to its potential as a drug target, VPS16 has also been identified as a potential biomarker for several neurological and cardiovascular disorders. The ability of VPS16 to regulate the activity of ion channels suggests that it may be involved in the regulation of neurotransmitter release and electrical activity in the brain and heart. This suggests that VPS16 may be a useful biomarker for the diagnosis and treatment of disorders that involve changes in ion channels, such as epilepsy, bipolar disorder, and cardiovascular disease.

The VPS16 gene has also been shown to be involved in the regulation of cell death and survival. In neurons, VPS16 has been shown to be involved in the regulation of apoptosis, which is a critical mechanism of cell death that helps to remove damaged or dysfunctional cells from the body. The dysfunction of VPS16 has been implicated in the development of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease.

In addition to its potential as a drug target and biomarker, VPS16 has also been shown to be involved in the regulation of other physiological processes that are important for human health. For example, VPS16 has been shown to be involved in the regulation of blood pressure and heart rate, which are critical for maintaining cardiovascular health. The dysfunction of VPS16 has been implicated in the development of cardiovascular disease, including hypertension and heart failure.

In conclusion, VPS16 is a gene that has the potential to be a drug target and biomarker for a variety of neurological and cardiovascular disorders. The regulation of ion channels by VPS16 is a critical mechanism that has been implicated in the development of a number of disorders. Further research is needed to fully understand the role of VPS16 in these disorders and to develop effective treatments.

Protein Name: VPS16 Core Subunit Of CORVET And HOPS Complexes

Functions: Plays a role in vesicle-mediated protein trafficking to lysosomal compartments including the endocytic membrane transport and autophagic pathways. Believed to act as a core component of the putative HOPS and CORVET endosomal tethering complexes which are proposed to be involved in the Rab5-to-Rab7 endosome conversion probably implicating MON1A/B, and via binding SNAREs and SNARE complexes to mediate tethering and docking events during SNARE-mediated membrane fusion. The HOPS complex is proposed to be recruited to Rab7 on the late endosomal membrane and to regulate late endocytic, phagocytic and autophagic traffic towards lysosomes. The CORVET complex is proposed to function as a Rab5 effector to mediate early endosome fusion probably in specific endosome subpopulations (PubMed:11382755, PubMed:23351085, PubMed:24554770, PubMed:25266290, PubMed:25783203). Required for recruitment of VPS33A to the HOPS complex (PubMed:23901104). Required for fusion of endosomes and autophagosomes with lysosomes; the function is dependent on its association with VPS33A but not VPS33B (PubMed:25783203). The function in autophagosome-lysosome fusion implicates STX17 but not UVRAG (PubMed:24554770)

The "VPS16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VPS16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets